Udvalget bemærkede også, at docetaxel er en standard førstevalgsbehandling for hormonresistent prostatacancer, og at det er sandsynligt, at de fleste patienter, som ville have effekt af Orplatna - behandling, ikke ville have haft effekt af docetaxel.
The Committee also noted that docetaxel is the standard first-line treatment for hormone-refractory prostate cancer, and that it is likely that most patients who would benefit from Orplatna treatment would have failed docetaxel treatment.